Topic
Who makes Ozempic, Wegovy and Zepbound?
Sourced profiles of Novo Nordisk and Eli Lilly, the two companies behind today's GLP-1 drugs.
Eli Lilly Market Cap: How Big It Is and How It Got ThereEli Lilly became the first drugmaker to reach a $1 trillion market value on November 21, 2025, driven by Mounjaro and Zepbound. As of September 2026, CompaniesMarketCap put its market cap at about $1.015 trillion, ranking it 15th among all companies; Nasdaq reported a higher same-day figure.Eli Lilly Pipeline: What Comes After ZepboundLilly's next obesity drug, retatrutide, delivered 28.3% (70.3 lbs) average efficacy-estimand weight loss at 80 weeks in Phase 3, with a BLA planned for Q1 2027. Behind it sit eloralintide, bimagrumab and the already-launched pill Foundayo. Here is where each asset stands.Eli Lilly vs Novo Nordisk: Who's Winning the Weight Loss Drug War?Yes. Eli Lilly holds 60.9% of the U.S. obesity and diabetes drug market versus Novo Nordisk's 38.8%, and Zepbound is the most-prescribed obesity drug. But Novo is winning the pill race, and the two are now fighting over pricing deals, FDA letters, ads and compounders.How Ozempic Changed Denmark's Economy — and What Came NextOzempic and Wegovy made Novo Nordisk so large that it accounted for one-fifth of Denmark's 2024 employment growth, while pharmaceutical exports helped the economy expand 3.7% — until competition helped cut the 2025 growth forecast to 1.4% and 9,000 layoffs followed.Novo Nordisk 2025 Crisis Explained: The Fall and the Fight BackNovo Nordisk lost nearly half its value in 2025: a July 29 profit warning wiped out $70 billion in market value in a day, the CEO was pushed out in May, 9,000 jobs were cut, and most of the board was replaced. Here is what happened, and what it means for Ozempic and Wegovy.Novo Nordisk Pipeline: What Comes After Wegovy in 2026 and BeyondNovo Nordisk's pipeline after Wegovy already includes two 2026 launches: the Wegovy pill and Wegovy HD (7.2 mg). Next up is CagriSema, with an FDA decision expected in Q4 2026, followed by zenagamtide in phase 3. Semaglutide's US patent protection runs to 2032.Who Makes Mounjaro and Zepbound? Eli Lilly, ExplainedMounjaro and Zepbound are both made by Eli Lilly and Company, an American drugmaker headquartered in Indianapolis, Indiana. Both brands contain the same active ingredient, tirzepatide, but they are FDA-approved for different uses.Who Makes Ozempic? Novo Nordisk, ExplainedOzempic is made by Novo Nordisk A/S, a Danish pharmaceutical company headquartered in Bagsværd, Denmark, run by president and CEO Maziar Mike Doustdar. The company reported DKK 309,064 million in 2025 net sales and is controlled by the Novo Nordisk Foundation through Novo Holdings.